Stevanato Group (NYSE:STVN) Posts Quarterly Earnings Results, Hits Estimates

Stevanato Group (NYSE:STVN) announced its quarterly earnings results on Thursday. The company reported €0.20 ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of €0.20 ($0.22), Zacks reports. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Stevanato Group updated its FY 2025 guidance to 0.544-0.587 EPS.

Stevanato Group Stock Up 2.4 %

Shares of NYSE STVN traded up €0.46 ($0.49) on Thursday, reaching €19.52 ($20.99). 308,786 shares of the company’s stock traded hands, compared to its average volume of 326,310. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The business’s 50 day simple moving average is €21.40 and its two-hundred day simple moving average is €20.51. Stevanato Group has a 12 month low of €16.56 ($17.81) and a 12 month high of €33.49 ($36.01). The company has a market cap of $5.91 billion, a price-to-earnings ratio of 41.53, a price-to-earnings-growth ratio of 7.18 and a beta of 0.56.

Analysts Set New Price Targets

STVN has been the subject of several research analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $23.00 target price (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Bank of America lifted their price objective on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Finally, Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of €28.60 ($30.75).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.